This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.
Patients ≥18 years with a history of cancer.
Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
Ability to understand a written informed consent form, and willing to sign it prior to study registration.
Patient <18 years.
Without a personal history of cancer.
Existing cardiomyopathy diagnosed after cancer diagnosis.
Documented cognitive impairment.
Cancer survivors at intermediate, high, or very high risk for developing cardiovascular disease will pursue a cardio-oncology visit.
Cohort
Prospective
Clinical Decision Aid
Other interventionThe clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
Standard Care
Other interventionCardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
Medication use
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject.
Medication use
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject.
Medication use
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject.
Imaging surveillance
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
